Journal articles: 'Yue du jiao xue'

1

Gao, Yue, Chun-Jie Liu, Hua-Yi Li, Xiao-Ming Xiong, Sjors G. j. g. In ‘t Veld, Gui-Ling Li, Jia-Hao Liu, et al. "Abstract LB168: Platelet RNA signature enables early and accurate detection of ovarian cancer: An intercontinental, biomarker identification study." Cancer Research 82, no. 12_Supplement (June 15, 2022): LB168. http://dx.doi.org/10.1158/1538-7445.am2022-lb168.

Full text

Abstract:

Abstract Background: Morpho-physiological alternations of platelets provided a rationale to harness RNA sequencing of tumor-educated platelets (TEPs) for preoperative diagnosis of cancer. Timely, accurate, and non-invasive detection of ovarian cancer in women with adnexal masses presents a significant clinical challenge. Patients and Methods: This intercontinental, hospital-based, diagnostic study included 761 treatment-naïve inpatients with histologically confirmed adnexal masses and 167 healthy controls from nine medical centers (China, n=3; Netherlands, n=5; Poland, n=1) between September 2016 and May 2019. The main outcomes were the performance of TEPs and their combination with CA125 in two Chinese (VC1 and VC2) and the European (VC3) validation cohorts collectively and independently. Exploratory outcome was the value of TEPs in public pan-cancer platelet transcriptome datasets. Results: The AUCs for TEPs in the combined validation cohort, VC1, VC2, and VC3 were 0.918 (95% CI 0.889-0.948), 0.923 (0.855-0.990), 0.918 (0.872-0.963), and 0.887 (0.813-0.960), respectively. Combination of TEPs and CA125 demonstrated an AUC of 0.922 (0.889-0.955) in the combined validation cohort; 0.955 (0.912-0.997) in VC1; 0.939 (0.901-0.977) in VC2; 0.917 (0.824-1.000) in VC3. For subgroup analysis, TEPs exhibited an AUC of 0.858, 0.859, and 0.920 to detect early-stage, borderline, non-epithelial diseases and 0.899 to discriminate ovarian cancer from endometriosis. Analysis of public datasets suggested that TEPs had potential to detect multiple malignancies (Table 1). Conclusions: TEPs had robustness, compatibility, and universality for preoperative diagnosis of ovarian cancer since it withstood validations in populations of different ethnicities, heterogeneous histological subtypes, early-stage ovarian cancer as well as other malignancies. However, these observations warrant prospective validations in a larger population before clinical utilities. Table 1. Performance for TEPs in public pan-cancer datasets. Disease n Healthy Control AUC, area under the curve (95% CI) Women NSCLC (non-small-cell lung cancer) 126 77 0.758 (0.691-0.825) Breast cancer 38 77 0.817 (0.726-0.909) Colorectal cancer 18 77 0.973 (0.945-1.000) Pancreatic cancer 16 77 0.993 (0.981-1.000) Glioblastoma 10 77 0.923 (0.831-1.000) Men NSCLC 119 82 0.746 (0.677-0.815) Colorectal cancer 25 82 0.933 (0.884-0.982) Pancreatic cancer 22 82 0.993 (0.984-1.000) Glioblastoma 19 82 0.981 (0.959-1.000) All NSCLC 245 159 0.774 (0.728-0.820) Colorectal cancer 40 159 0.978 (0.961-0.996) Breast cancer 38 159 0.821 (0.736-0.906) Pancreatic cancer 35 159 0.987 (0.974-0.999) Glioblastoma 35 159 0.931 (0.890-0.972) Hepatobiliary carcinomas 14 159 0.991 (0.978-1.000) Citation Format: Yue Gao, Chun-Jie Liu, Hua-Yi Li, Xiao-Ming Xiong, Sjors G.j.g. In ‘t Veld, Gui-Ling Li, Jia-Hao Liu, Guang-Yao Cai, Gui-Yan Xie, Shao-Qing Zeng, Yuan Wu, Jian-Hua Chi, Qiong Zhang, Xiao-Fei Jiao, Lin-Li Shi, Wan-Rong Lu, Wei-Guo Lv, Xing-Sheng Yang, Jurgen M.j. Piek, Cornelis D de Kroon, C.a.r. Lok, Anna Supernat, Sylwia Łapińska-Szumczyk, Anna Łojkowska, Anna J. Żaczek, Jacek Jassem, Bakhos A. Tannous, Nik Sol, Edward Post, Myron G. Best, Bei-Hua Kong, Xing Xie, Ding Ma, Thomas Wurdinger, An-Yuan Guo, Qing-Lei Gao. Platelet RNA signature enables early and accurate detection of ovarian cancer: An intercontinental, biomarker identification study [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr LB168.

APA, Harvard, Vancouver, ISO, and other styles

2

Wang, Xue, Feng Du, Jian Yue, Yiran Si, Lina Cui, Bei Zhang, Xiaochen Zhao, Binghe Xu, and Peng Yuan. "Abstract 5084: KMT2D and PIK3CA mutation as potential factors to predict adjuvant chemotherapy efficacy in surgical triple negative breast cancer." Cancer Research 82, no. 12_Supplement (June 15, 2022): 5084. http://dx.doi.org/10.1158/1538-7445.am2022-5084.

Full text

Abstract:

Abstract Background: Chemotherapy is the most common treatment strategy for triple negative breast cancer (TNBC) patients. Nevertheless, due to adverse drug reactionsthe molecular high heterogeneity of TNBC and no appropriate meaningful efficacy markers, it is still difficult to establish preferred therapeutic strategies and predict the outcomes for TNBC. This study was to investigate the potential predictors and therapeutic targets based on genetic features. Methods: A total of 386 TNBC patients were randomized 1:1 to receive either six cycles of paclitaxel + cisplatin (TP) or four cycles of epirubicin + cyclophosphamide followed by four cycles of docetaxel (EC-T) adjuvant chemotherapy after surgery (NCT01150513), which were described previously. Finally, 149 TNBC patients with clinical and tumor sequencing data availability were retrospectively analysed by NGS for 733 cancer-related genes. All tumor samples were collected during the surgical operation and subjected to NGS for evaluating genomic mutations and the potential predictors. Cox regression model and Kaplan-Meier method were applied to evaluate disease-free survival (DFS). Results: In the surgical cohort receiving adjuvant chemotherapy, 74 patients received platinum and 75 received platinum-free chemotherapy as adjuvant chemotherapy. The most frequently mutated genes in this surgical TNBC cohort were TP53 (84%), BRCA1 (18%), BRCA2 (15%), POL1 (13%), PTEN (12%), REV3L (11%), FANCC (10%), and PARP4 (10%). We analyzed the associations between 733 cancer-related gene mutations and DFS after adjuvant chemotherapy. For the TP group, PIK3CA mutation (19%, 14/74) was discovered to correlate with poor DFS for patients treated with platinum-containing adjuvant therapy (HR=3.2, P=0.037), and KMT2D mutation (15%, 11/75) display worse DFS for patients treated with EC-T platinum-free group (HR=3.0, p=0.039). However, BRCA1/2 mutation (24%, 35/149) was found to be associated with poor prognosis (HR=2.1 (95% CI: 1-4.6), p=0.047), irrespective of therapeutic regimen. Conclusions: In this population of surgical TNBC patients, NGS analysis identified potential predictive markers. PIK3CA mutation in TP platinum-containing group and KMT2D mutation in EC-T platinum-free group were significantly associated to poor prognosis for adjuvant chemotherapy in triple negative breast cancer. Citation Format: Xue Wang, Feng Du, Jian Yue, Yiran Si, Lina Cui, Bei Zhang, Xiaochen Zhao, Binghe Xu, Peng Yuan. KMT2D and PIK3CA mutation as potential factors to predict adjuvant chemotherapy efficacy in surgical triple negative breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5084.

APA, Harvard, Vancouver, ISO, and other styles

3

Yue, Jian, Xue Wang, Jie Ju, Zixiang Yang, Tong Wei, Peng Yuan, Min Gao, Ling Xu, and Yin Guan. "Abstract PO4-05-04: Comparative effectiveness of Palbociclib plus Aromatase inhibitor versus fulvestrant alone as initial endocrine therapy for HR+/HER2- advanced breast cancer in Chinese clinical practice: a real-world study." Cancer Research 84, no. 9_Supplement (May 2, 2024): PO4–05–04—PO4–05–04. http://dx.doi.org/10.1158/1538-7445.sabcs23-po4-05-04.

Full text

Abstract:

Abstract Background: In the real world, there are still a large number of HR+/HER2- advanced breast cancer patients receiving initial endocrine therapy with fulvestrant monotherapy in China, especially patients with bone metastases only. It is due to lack of data comparing the effective between Palbociclib combined with AI and fulvestrant monotherapy as initial endocrine therapy. On the other hand, there are economic factors and access issues. According to the National Cancer Center's previous clinical experience, Palbociclib combined with AI is superior to fulvestrant monotherapy in HR+/HER2- advanced breast cancer patients receiving initial endocrine therapy. Therefore, we collected and summarized the previous clinical data in our center to compare the effective of Palbociclib combined with AI and fulvestrant monotherapy for HR+/HER2-advanced breast cancer patients receiving initial endocrine therapy in China. Patients and methods: This is a retrospective real-world study of multicenter studies. It aimed at verifying the effective of Palbociclib combined with AI and fulvestrant monotherapy for HR+/HER2-advanced breast cancer patients receiving initial endocrine therapy in China. A total of 392 patients with ≥3 months of follow-up received Palbociclib plus AI or fulvestrant alone in the first-line setting between April 1, 2015 and February 1, 2023. Stabilized inverse probability treatment weighting (sIPTW) was used to balance baseline demographic and clinical characteristics. Real-world progression-free survival (rwPFS) and overall survival (OS) were analyzed. Results: After sIPTW adjustment, a median follow-up of 37 months (range 34-40) in the Palbociclib group and 59 months (range 56-61) in those taking fulvestrant alone. Palbociclib combination regiment was associated with significantly longer median rwPFS compared to fulvestrant alone (22.0 vs 14.0 months; HR,0.469;95% CI 0.370–0.594, p< 0·0001). Median OS was not reached in the Palbociclib group and was 57 months (95% CI 54.0–66.0) in the fulvestrant group(HR,0.666; 95% CI 0.437–1.017, p< 0·94). Conclusion: In the real-world population of patients, palbociclib combined with AI endocrine therapy is superior to fulvestrant monotherapy in HR+/HER2- advanced breast cancer patients receiving initial endocrine therapy. PFS and OS before IPTW PFS and OS after IPTW Table patient characteristics Citation Format: Jian Yue, Xue Wang, Jie Ju, Zixiang Yang, Tong Wei, Peng Yuan, Min Gao, Ling Xu, Yin Guan. Comparative effectiveness of Palbociclib plus Aromatase inhibitor versus fulvestrant alone as initial endocrine therapy for HR+/HER2- advanced breast cancer in Chinese clinical practice: a real-world study [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PO4-05-04.

APA, Harvard, Vancouver, ISO, and other styles

4

Liu, Pinghua, and Na Liu. "The rites and music education in Zhu Zi's Xiao Xue." Advances in Education, Humanities and Social Science Research 2, no. 1 (September 20, 2022): 154. http://dx.doi.org/10.56028/aehssr.2.1.154.

Full text

Abstract:

Chinese civilization has always been called "rites and music civilization"(li-yue-wen-ming ). It is also the due meaning of sacred education to educate the people and change customs with rites and music. Chinese sage education aims to cultivate benevolent gentlemen with five constant virtues, which are based on benevolence, and this benevolence is embodied in the civilization of rites and music in Chinese society. It is precisely because of "the substance and function relationship"(ti-yong-guan-xi ) between benevolence and "the system of rites and music"(li-yue-zhi-du ) that Zhu Zi's Xiao Xue education pays particular attention to cultivating gentlemen with ideal personality through rites and music education.

APA, Harvard, Vancouver, ISO, and other styles

5

Liu, Pinghua, and Na Liu. "The rites and music education in Zhu Zi's Xiao Xue." Advances in Education, Humanities and Social Science Research 1, no. 2 (September 20, 2022): 154. http://dx.doi.org/10.56028/aehssr.1.2.154.

Full text

Abstract:

Chinese civilization has always been called "rites and music civilization"(li-yue-wen-ming ). It is also the due meaning of sacred education to educate the people and change customs with rites and music. Chinese sage education aims to cultivate benevolent gentlemen with five constant virtues, which are based on benevolence, and this benevolence is embodied in the civilization of rites and music in Chinese society. It is precisely because of "the substance and function relationship"(ti-yong-guan-xi ) between benevolence and "the system of rites and music"(li-yue-zhi-du ) that Zhu Zi's Xiao Xue education pays particular attention to cultivating gentlemen with ideal personality through rites and music education.

APA, Harvard, Vancouver, ISO, and other styles

6

Xue, Wei-Wei, Huan-Nan Wang, Zhi-Meng Wang, Meng-Xi Qiu, Jing Che, Feng-Jiao Deng, and Jiang-Dong Liu. "Cloning and Characterization of ifitm1 and ifitm3 Expression During Early Zebrafish Development - CORRIGENDUM." Zygote 24, no. 1 (July 21, 2015): 159. http://dx.doi.org/10.1017/s0967199415000398.

Full text

Abstract:

The authors apologise for errors in the corresponding authors details given on page 1 of the article. Below is the correct information of the corresponding author and email address :1) Wei-Wei Xue, Huan-Nan Wang, Zhi-Meng Wang, Meng-Xi Qiu, Jing Che, Feng-Jiao Deng* and Jiang-Dong Liu*2) *All correspondence to: Feng-Jiao Deng and Jiang-Dong Liu. e-mail: fish4@whu.edu.cn3) All authors are from the same one laboratory. The second laboratory was superfluous and should be deleted.

APA, Harvard, Vancouver, ISO, and other styles

7

Wang, Xue, Jian Yue, Jiayu Wang, Pin Zhang, Fei Ma, Binghe Xu, and Peng Yuan. "Abstract P3-02-07: Combined Chemo-endocrine Therapy Maybe a New Option for HR+/HER2− Advanced Breast Cancer: A Prospective, Single-center Clinical Study of Fulvestrant plus Oral Vinorelbine." Cancer Research 83, no. 5_Supplement (March 1, 2023): P3–02–07—P3–02–07. http://dx.doi.org/10.1158/1538-7445.sabcs22-p3-02-07.

Full text

Abstract:

Abstract Background Fulvestrant have demonstrated synergistic antitumor effect with chemotherapy regimen. This study evaluates the efficacy and safety of Fulvestrant with Vinorelbine in patients with hormone receptor positive (HR+)/human epidermal growth factor receptor-2-negative (HER2−) recurrent or metastatic breast cancer. Methods In this prospective, single-arm and investigator-initiated clinical study, patients with recurrent or metastatic HR+/HER2− breast cancer after the first line adjuvant endocrine therapy for > 1 year were eligible, in which the subjects of the first line was defined as the patients with recurrence and metastasis after adjuvant endocrine therapy for over 1 year and did not receive treatment for the recurrence and metastasis and the second-line defined as the patients who had disease progression after receiving first-line endocrine therapy or first-line chemotherapy). Patients were administered i.m. Fulvestrant 500mg (day 1 per cycle for 28 days) and oral Vinorelbine (60 mg/m2 on day 1, 8 and 15 of each cycle). The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), objective response rate (ORR), disease control rate (DCR), duration of response (DoR), and safety. The Kaplan–Meier method and log-rank test were used to evaluate PFS and OS. Results Total 38 HR+/HER2- advanced breast cancer patients with median follow-up time (25.1 months) were enrolled in, and median PFS [9.86 months (95% CI: 7.2, 23.13)] were discovered. The median PFS of the first-line and the second-line treatment population were 20.73 months (95% CI: 9.82, NR) and 4.27 months (95% CI: 3.68, NR), respectively. The median OS of the intent-to-treat (ITT) and the first-line treatment population were not reached, and the OS of the second-line treatment was 28.2 months (95% CI: 11.5, NR). The ORR of the ITT population was 39.47% (95% CI: 23.93, 55.01). The ORR of the patients receiving first-line and second-line treatments were 44.44% (95% CI: 25.70, 63.19) and 27.27% (95% CI: 0.95, 53.59), respectively. The DCR of ITT population was 92.11% (95% CI: 83.54, 100.00)], and the median DoR was approximately 15.33 months (95% CI: 7.23, 22.54)]. In the safety analysis, most of the adverse events were grade of 1/2, and none of grade 4/5 adverse events were reported. Conclusion This is the first exploratory study of Fulvestrant with oral Vinorelbine regimen in the treatment of HR+/HER2− recurrent and metastatic breast cancer conducted worldwide. The combinative chemo-endocrine therapy was efficacious, safe and promising for patients with HR+/HER2− advanced breast cancer. Citation Format: Xue Wang, Jian Yue, Jiayu Wang, Pin Zhang, Fei Ma, Binghe Xu, Peng Yuan. Combined Chemo-endocrine Therapy Maybe a New Option for HR+/HER2− Advanced Breast Cancer: A Prospective, Single-center Clinical Study of Fulvestrant plus Oral Vinorelbine [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P3-02-07.

APA, Harvard, Vancouver, ISO, and other styles

8

Wang, Xue, Yimeng Chen, Feng Du, Jian Yue, Yiran Si, Xiaochen Zhao, Lina Cui, et al. "Abstract 5689: Effects of homologous recombination-related gene mutation subtypes on gene instability and the efficacy of platinum-containing regiments in triple-negative breast cancer." Cancer Research 82, no. 12_Supplement (June 15, 2022): 5689. http://dx.doi.org/10.1158/1538-7445.am2022-5689.

Full text

Abstract:

Abstract Background: Platinum-containing chemotherapy is treatment with high efficacy in homologous recombination (HR) deficient cancers that arise in carriers of mutations in the BRCA1/2 genes. However, previous reports have shown that TNBC patients carrying no BRCA1/2 mutations also could benefit from platinum therapy. This study aimed to explore the association between HR-related gene mutations and genomic instability, and further evaluate the effectiveness of platinum-containing chemotherapy preliminarily. Methods: A total of 386 TNBC patients were screened from a surgical cohort (NCT01150513) and a metastatic cohort. Finally, 189 TNBC patients with clinical and tumor sequencing data availability were included, including 149 patients treated with radical surgery and adjuvant chemotherapy. All tumor samples were collected during the surgical operation and subjected to NGS for evaluating homologous recombination deficiency (HRD) score and 15 HR-related gene pathogenic or likely pathogenic mutations (including ATM, BARD1, BRCA1, BRCA2, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51D, RAD51C, RAD54L). HRD score was an algorithmic assessment of three biomarkers of genomic instability as loss of heterozygosity, telomeric-allelic imbalance, large-scale state transitions and based on over 10,000 single-nucleotide polymorphisms in the human genome. Results: In 189 TNBC cohort, 40 patients (21.1%) had BRCA1/2 deleterious mutations, with additional 26 patients (13.8%) carrying mutations in HR-related genes other than BRCA1/2. Compared with BRCA1/2-intact patients, those carrying BRCA1/2m displayed a significantly higher HRD score (median, 35.5 vs 20.0; P=0.02). However, patients with HRm obtained a similar HRD score with HRwt patients (median, 28.0 vs 21.0, P=0.83). TNBC patients with PALB2m (n=8) had a small trend higher HRD score compared with BRCA1/2m (median HRD score 39.0 and 35.5), and TNBC patients with RAD51 family (n=7), ATM (n=5) and other HR-related gene mutations had a numerical trend lower HRD score compared with BRCA1/2m (median HRD score 22.0, 4.0, 14.5 and 35.5). Of the 149 patients in surgical cohort, 74 received platinum-containing, and 75 underwent platinum-free adjuvant chemotherapy. We analyzed the associations between HR-related gene mutations and disease-free survival (DFS), and found that patients with RAD51Bm (n=3), RAD51Cm (n=1) or PPP2R2Am (n=1) displayed worse DFS for patients treated with adjuvant chemotherapy (P =0.012, P<0.0001 or P<0.0001, respectively). Conclusions: In this study, we found that different HR-related genes mutation subtypes may exert distinct effects on genomic instability, and mutations in HR-related genes beyond the context of BRCA1/2 may serve as a biomarker for platinum-based adjuvant therapy for TNBC patients, which warrants further studies. Citation Format: Xue Wang, Yimeng Chen, Feng Du, Jian Yue, Yiran Si, Xiaochen Zhao, Lina Cui, Bei Zhang, Ting Bei, Peng Yuan, Binghe Xu. Effects of homologous recombination-related gene mutation subtypes on gene instability and the efficacy of platinum-containing regiments in triple-negative breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5689.

APA, Harvard, Vancouver, ISO, and other styles

9

LIU, Guoxuan. "A Complementary Research on Guang Jiao chou lue (《廣校讎略》) and Jiao Chou Xue (《校讎學》)." Journal of Chinese Characters 16 (December 30, 2016): 139–49. http://dx.doi.org/10.14772/cscck.2016.16.139.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Chen, Yimeng, Xue Wang, Feng Du, Jian Yue, Yiran Si, Lina Cui, Bei Zhang, Binghe Xu, and Peng Yuan. "Abstract P1-08-12: The status of homologous recombination deficiency is a potential biomarker for platinum-based chemotherapy in triple-negative breast cancer." Cancer Research 82, no. 4_Supplement (February 15, 2022): P1–08–12—P1–08–12. http://dx.doi.org/10.1158/1538-7445.sabcs21-p1-08-12.

Full text

Abstract:

Abstract BackgroundTriple-negative breast cancer (TNBC) is a subtype of breast cancer that is highly susceptible to recurrence and metastasis. The therapeutic drugs are limited due to the lack of effective biomarkers predicting the therapeutic efficacy and prognosis of disease. Previous studies have shown that platinum-containing regimens are effective for both early and advanced TNBC, therefore, it is particularly important to explore biomarkers for predicting the efficacy of platinum drugs and to screen the population sensitive to platinum drugs. Methods All patients with available tumor specimens from National Cancer Center in China were eligible for this prospective-retrospective study (n=189), including 149 patients with early TNBC (NCT01150513, CH-BC-007) and 40 patients with advanced TNBC (12-123/657, CH-BC-018) who are treated with or without platinum. The primary endpoint is disease-free survival (DFS) for early TNBC and progression free survival (PFS) for advanced TNBC. For HRD status and genomic signatures, indexed libraries were subjected to probe-based hybridization with a customized NGS panel targeting 733 cancer-related genes. 3DMed-HRD algorithm was evaluated based on loss of heterozygosity score (LOH), telomeric allelic imbalance score (TAI) and large-scale state transition score (LST) to characterize genomic instability using over 10,000 single-nucleotide polymorphisms distributed across human genome, adjusted by tumor ploidy and purity. HRD positive is defined by HRD score above the threshold (cut-off ≥30) and/or deleterious mutation in BRCA1/2. ResultsDeleterious BRCA1/2 mutations were detected in 21.2% (40/189) of TNBC patients and 48.1% (91/189) were defined as HRD positive. In advanced TNBC cohort, 21 patients received platinum-containing and 19 received platinum-free chemotherapy regimens for first-line chemotherapy. The progression-free survival (PFS) of the platinum-containing group was longer than that of the platinum-free group (median PFS 9.13 vs 2.97 months, HR 0.39, 95%CI, 0.19-0.81, P=0.011), and the PFS of patients with HRD positive was significantly longer than HRD negative patients (median PFS 13.6 vs 6.80 months, HR 0.38, 95%CI, 0.15-0.99, P=0.048) in platinum-containing group. Interestingly, HRD-positive patients have a significantly shorter PFS than HRD-negative in platinum-free group (median PFS 1.97 vs 4.52 months, HR 3.67, 95%CI, 1.20-11.22, P=0.023). For the HRD-positive patients, median PFS was significantly better in platinum-based group than platinum-free group (median PFS 13.6 vs 1.97 months, HR 0.12, 95%CI, 0.03-0.43, P=0.001). In early-stage TNBC cohort (n=149), 74 patients received platinum-containing and 75 received platinum-free chemotherapy regimens for adjuvant chemotherapy. In platinum-containing group, no statistically significant difference was found in DFS between HRD-positive and HRD-negative patients (P=0.118). High-risk TNBC group (Ki-67 ≥ 15%) analysis revealed that HRD-positive patients had a numerical better DFS than HRD-negative patients (HR 0.43, 95%CI, 0.12-1.50, P=0.180). Among patients with HRD-positive, patients in platinum-containing group had a tendency to benefit more than those in platinum-free group (HR 0.35, 95%CI, 0.11-1.10, P=0.062). Conclusions: We developed a novel algorithm to evaluate 3DMed-HRD status and highlights the potential utility of HRD in guiding chemotherapy for TNBC patients in this retrospective analysis. In comparison to platinum-free chemotherapy, the advanced TNBC HRD positive patients with advanced TNBC receiving platinum-based chemotherapy is a preferable regimen, and the HRD negative patients might be on the contrary. Prospective validation with larger sample size is needed. Citation Format: Yimeng Chen, Xue Wang, Feng Du, Jian Yue, Yiran Si, Lina Cui, Bei Zhang, Binghe Xu, Peng Yuan. The status of homologous recombination deficiency is a potential biomarker for platinum-based chemotherapy in triple-negative breast cancer [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P1-08-12.

APA, Harvard, Vancouver, ISO, and other styles

11

김명신. "The Characteristic of Knight-errant Romantic novels in Hangul Xue-Yue-Mei-Zhuan(雪月梅傳)." Journal of the research of chinese novels ll, no. 33 (April 2011): 125–43. http://dx.doi.org/10.17004/jrcn.2011..33.007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Tseng, Chu-Yao, Ching-Wen Huang, Hsin-Chia Huang, and Wei-Chen Tseng. "Utilization Pattern of Traditional Chinese Medicine among Fracture Patients: A Taiwan Hospital-Based Cross-Sectional Study." Evidence-Based Complementary and Alternative Medicine 2018 (September 30, 2018): 1–9. http://dx.doi.org/10.1155/2018/1706517.

Full text

Abstract:

Traditional Chinese medicine (TCM) divides fracture treatment into three stages. Many TCM herbs and formulas have been used to treat fractures for thousands of years. However, research regarding the Chinese herbal products (CHPs) that should be used at different periods of treatment is still lacking. This study aims to identify the CHPs that should be used at different periods of treatment as well as confirm the TCM theory of fracture periods medicine. We used prescriptions of TCM outpatients with fracture diagnoses analyzed using the Chang Gung Research Database (CGRD) from 2000 to 2015. According to the number of days between the date of the fracture and the clinic visit date, all patients were assigned to one of three groups. Patients with a date gap of 0-13 days were assigned to the early period group; those with a date gap of 14-82 days were assigned to the middle period group; and those with a date gap of 83-182 days were assigned to the late period group. We observed the average number of herbal formulas prescribed by the TCM doctor at each visit was 2.78, and the average number of single herbs prescribed was 6.47. The top three prescriptions in the early fracture period were Zheng-gu-zi-jin-dang, Shu-jing-huo-xue-tang, and Wu-ling-san. In the middle fracture period, the top three formulas were Zheng-gu-zi-jin-dang, Shu-jing-huo-xue-tang, and Zhi-bai-di-huang-wan. In the late fracture period, the top three formulas were Shu-jing-huo-xue-tang, Gui-lu-er-xian-jiao, and Du-huo-ji-sheng-tang. The main single herbs used in the early fracture period were Yan-hu-suo, Gu-sui-bu, and Dan-shen. From the middle to the late period, the most prescribed single herbs were Xu-duan, Gu-sui-bu, and Yan-hu-suo. We concluded that the results showed that the CGRD utilization pattern roughly meets the TCM theory at different fracture periods.

APA, Harvard, Vancouver, ISO, and other styles

13

XUE, MING, HONGBO XÜ, YUMING LIU, and DICK K. P. YUE. "Computations of fully nonlinear three-dimensional wave–wave and wave–body interactions. Part 1. Dynamics of steep three-dimensional waves." Journal of Fluid Mechanics 438 (July 5, 2001): 11–39. http://dx.doi.org/10.1017/s0022112001004396.

Full text

Abstract:

We develop an efficient high-order boundary-element method with the mixed-Eulerian–Lagrangian approach for the simulation of fully nonlinear three-dimensional wave–wave and wave–body interactions. For illustration, we apply this method to the study of two three-dimensional steep wave problems. (The application to wave–body interactions is addressed in an accompanying paper: Liu, Xue & Yue 2001.) In the first problem, we investigate the dynamics of three-dimensional overturning breaking waves. We obtain detailed kinematics and full quantification of three-dimensional effects upon wave plunging. Systematic simulations show that, compared to two-dimensional waves, three-dimensional waves generally break at higher surface elevations and greater maximum longitudinal accelerations, but with smaller tip velocities and less arched front faces. For the second problem, we study the generation mechanism of steep crescent waves. We show that the development of such waves is a result of three-dimensional (class II) Stokes wave instability. Starting with two-dimensional Stokes waves with small three-dimensional perturbations, we obtain direct simulations of the evolution of both L2 and L3 crescent waves. Our results compare quantitatively well with experimental measurements for all the distinct features and geometric properties of such waves.

APA, Harvard, Vancouver, ISO, and other styles

14

Goldin, Paul Rakita. "Xunzi in the Light of the Guodian Manuscripts." Early China 25 (2000): 113–46. http://dx.doi.org/10.1017/s0362502800004284.

Full text

Abstract:

This article discusses the several previously unknown Confucian texts discovered in 1993 in a Warring States tomb at Guodian, near Jingmen, Hubei Province. I believe that these works should be understood as doctrinal material deriving from a single tradition of Confucianism and datable to around 300 B.C. Of the surviving literature from the same period, they are closer to the Xunzi than to any other text, and anticipate several characteristic themes in Xunzi's philosophy. These are: the notion of human nature (xing 性),and the controversy over whether the source of morality is internar or “external”; the role of learning (xue 學)and habitual practice (xi 習) in moral development; the content and origin of ritual (li 禮), by which human beings accord with the Way; the conception of the ruler as the mind (xin 心) of the state; and the psychological utility of music (yue 樂) in inculcating proper values.It is especially important for scholars to take note of these connections with Xunzi, in view of the emerging trend to associate the Guodian manuscripts with Zisi, the famous grandson of Confucius, whom Xunzi bitterly criticized.

APA, Harvard, Vancouver, ISO, and other styles

15

Zhou, Ziqi, Pan Geng, Wei Cao, and Xiaoyan Xu. "Research on Speed Cooperative Control Strategy for Rudderless Dual-PMSM Propulsion Ships." Journal of Marine Science and Engineering 12, no. 2 (February 1, 2024): 266. http://dx.doi.org/10.3390/jmse12020266.

Full text

Abstract:

In the navigation of rudderless dual-motor propulsion ships, it is often necessary for the dual motor to run stably at different given speeds. However, the existing coupling strategies cannot achieve precise cooperative control of the dual motor under different given commands. Therefore, in this study, we proposed a variable error difference compensation-coupling control (VEDC-CC) strategy. Simultaneously, a coupling compensation coefficient determination method based on the self-error difference of the dual motor was introduced. The VEDC-CC utilizes the self-error difference of the dual motor as the input for the coupling compensation controller, which enables the mutual coupling of self-errors, and effectively improves the cooperative controlling performance under different given commands. Moreover, the employed variable compensation coefficient determination method enhances the disturbance coupling performance and the response speed of the system. In this study, we analyzed the different navigation conditions and dual-propeller load characteristics of a rudderless dual-motor propulsion ship. Taking a rudderless dual-motor propulsion ship designed based on the cruise ship “Feng Hua Xue Yue” as the object, the VEDC-CC strategy was validated through simulation tests, considering the propeller load characteristics and actual operating conditions. The experimental results demonstrated that the VEDC-CC strategy could meet the practical control needs of the target ship.

APA, Harvard, Vancouver, ISO, and other styles

16

Li, Chenyang, and Wang Shanbo [wang][shan][bo]. "Zhuiqiu kexue jingshen: Zhong-Xi kexue bijiao yu rongtong de zhexue toushi [zhui][qiu][ke][xue][jing][shen] : [zhong][xi][ke][xue][bi][jiao][yu][rong][tong][de][zhe][xue][tou][shi] (Seeking the Soul of Science: Science in China and the West Compared through an Understanding of Philosophical Perspective)." Philosophy East and West 49, no. 1 (January 1999): 86. http://dx.doi.org/10.2307/1400122.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Du, Jun, Taolin Liu, Wanbo Tang, Yue Zhang, Limin Zhao, Xin Jiao, Chao Sun, et al. "Abstract 2752: Targeting intracellular tumor antigens using fully human TCR mimic antibodies derived from HLA transgenic RenMiceTM." Cancer Research 83, no. 7_Supplement (April 4, 2023): 2752. http://dx.doi.org/10.1158/1538-7445.am2023-2752.

Full text

Abstract:

Abstract Therapeutic antibodies have ushered in a new age of cancer immunotherapy. Historically, these therapies have targeted a limited subset of soluble and cell surface tumor-associated antigens (TAAs). T cell receptors (TCRs) on cytotoxic CD8+ T cells recognize peptide antigens bound to major histocompatibility class I (MHC-I) proteins, called HLA-A/B/C in humans. By this pathway, antigen is regularly sampled from the intracellular peptidome, processed, and presented to cytotoxic T cells. Expanding TCR-based recognition of soluble, intracellular TAAs presented on the surface of malignant cells by this mechanism is a propitious therapeutic strategy. Here we describe a novel platform for generating T cell receptor mimic (TCRm) antibodies using our humanized immunoglobulin (RenMabTM) mice engineered to express HLA. TCRm antibodies have the same binding properties as endogenous TCRs and recognize processed, HLA-bound peptides including intracellular tumor-associated antigens, viral oncoproteins, and cancer-testis antigen (CTA). TCRm antibodies bind peptide-HLA with high specificity and up to nanomolar affinity. Our optimized immunization protocols and high-throughput screening methods allow for one-step TCRm antibody generation. TCRm antibodies can also be used to assemble bispecific T cell engaging antibodies (BiTEs) to enhance tumor targeting of cytotoxic T cells. Biocytogen’s TCRm antibodies are a flexible and powerful tool for cancer immunotherapy. By enabling TCR-mediated recognition of an unrestricted repertoire of cancer neoantigens, TCRm antibodies may find broad clinical application. Citation Format: Jun Du, Taolin Liu, Wanbo Tang, Yue Zhang, Limin Zhao, Xin Jiao, Chao Sun, Pengfei Du, Yuqi Zhang, Baihong Liu, Qingcong Lin, Yi Yang. Targeting intracellular tumor antigens using fully human TCR mimic antibodies derived from HLA transgenic RenMiceTM [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 2752.

APA, Harvard, Vancouver, ISO, and other styles

18

Deng, Xinxin, Yanna Jiao, Huifeng Hao, Zhengwang Guo, Dong Xue, and Shuyan Han. "Abstract 5435: CUEDC2 involved in the inhibitory effect of dandelion on triple-negative breast cancer stem cells." Cancer Research 84, no. 6_Supplement (March 22, 2024): 5435. http://dx.doi.org/10.1158/1538-7445.am2024-5435.

Full text

Abstract:

Abstract Background: Cancer stem cells (CSCs) exert a substantial influence on the initiation, progression, and metastasis of triple-negative breast cancer (TNBC). Dandelion has exhibited encouraging outcomes in impeding the proliferation of TNBC cells. Nevertheless, the extent of investigation regarding the efficacy of dandelion in targeting CSCs remains restricted. Purpose: The aim of this study was to investigate the impact of dandelion extract (DE) on CSCs properties. Methods: In vitro experiments were conducted using TNBC cell lines. Mice bearing TNBC tumors were established for in vivo investigations. Biochemical analysis and cell biological assay were carried to evaluate the effect of dandelion and the underlying mechanisms. Results: DE treatment significantly decreased the proportion of ALDH+ cells, mammosphere formation ability, and CSCs-related markers. CUEDC2 is highly expressed in ALDH+ TNBC cells, and its overexpression increased the expression of markers related to CSCs. Conversely, the tumor growth was impeded in CUEDC2 KO mice and the markers related to CSCs also were also reduced. CUEDC2 overexpression reversed the inhibitory effect of DE on TNBC CSCs properties. Mechanistically, CUEDC2 related pathway involved in the inhibitory effect of DE on TNBC CSCs properties. Conclusion: CUEDC2 played a crucial role in maintaining the stem cell properties of TNBC. DE inhibit the self-renewal of TNBC stem cells by regulating the CUEDC2 related signaling pathway. Keywords: Dandelion; CUEDC2; Triple-negative breast cancer; Cancer stem cell. Citation Format: Xinxin Deng, Yanna Jiao, Huifeng Hao, Zhengwang Guo, Dong Xue, Shuyan Han. CUEDC2 involved in the inhibitory effect of dandelion on triple-negative breast cancer stem cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 5435.

APA, Harvard, Vancouver, ISO, and other styles

19

Zhang, Liyi, Qi Zhang, Pei Li, Min Xiong, Yue Zhou, Jingyan Xue, Ming Chen, et al. "Abstract P3-05-46: scRNA-seq profiling reveals different tumor immune-microenvironment in triple negative breast cancer and decodes pivotal role of THBS1- SDC1 axis in tumor metastasis." Cancer Research 83, no. 5_Supplement (March 1, 2023): P3–05–46—P3–05–46. http://dx.doi.org/10.1158/1538-7445.sabcs22-p3-05-46.

Full text

Abstract:

Abstract ABSTRACT Background: Breast cancer has become the most common cancer worldwide and triple-negative breast cancer (TNBC) is the most aggressive subtype due to the lacks of hormone receptors and HER2 expression. Increasing rate of breast cancer metastasis also need to be solved. Nearly one in four breast cancer patients developed metastasis after treatment, which attributed to 90% cancer related death. Considering highly aggressive pattern of TNBC, TNBC showed higher metastasis probability rather than other subtypes. Therefore, exploring more biomarkers and therapeutic targets are on urgent. Methods: We profiled the transcriptomes of 59646 cells from 12 primary and 4 metastatic tumor samples from Gene Expression Omnibus (GEO) database (https://www.ncbi.nlm.nih.gov/geo/). Results: Comparing with primary site, metastatic site was predominated with immunosuppressive tumor microenvironment. In brief, metastatic samples showed increasing numbers of macrophages, lower anti-tumor microenvironment scores, higher malignant cell properties scores, less effective T cells and macrophages, enhanced immune escape potential tumor cells and a later pseudotime state of malignant cells, compared with primary samples. Remarkably, metastatic samples exhibited a stronger interaction of THBS1-SDC1 axis between macrophage subcluster named angiogenesis-1 and malignant cell subcluster named CDKN2A epithelial cells. We subsequently confirmed that higher THBS1-SDC1 expression indicated with poor overall survival and distant metastatic free survival of TNBC patients in The Cancer Genome Atlas (TCGA) TNBC cohort. Conclusion: Our immune landscape of TNBC ecosystem provide deeper insights into tumor metastasis and offer potential biomarkers and therapeutic target for TNBC. Key words: Breast cancer; immune-microenvironment; THBS1; SDC1; metastasis Citation Format: Liyi Zhang, Qi Zhang, Pei Li, Min Xiong, Yue Zhou, Jingyan Xue, Ming Chen, Wei-Ru Chi, Hengyu Ren, Chih Wan Goh, Douwaner Liu, Liren Wangxu, Yayun Chi, Bingqiu Xiu, Jiong Wu. scRNA-seq profiling reveals different tumor immune-microenvironment in triple negative breast cancer and decodes pivotal role of THBS1- SDC1 axis in tumor metastasis [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P3-05-46.

APA, Harvard, Vancouver, ISO, and other styles

20

Zhou, Yaqian. "Research on Academic Guidance Model Based on Counselor Service Room under the “All Students, All Process and All-round Education”: “Yue Xue” Service Room of Southwest Petroleum University as an Example." Journal of International Education and Development 5, no. 7 (2021): 146–50. http://dx.doi.org/10.47297/wspiedwsp2516-250028.20210507.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Hu, Jie, Haoran Tang, Feng Xie, Yue Zhang, Shidong Jia, and Jian Zhou. "Abstract 1020: Tissue-informed ctDNA MRD assay detects post-surgery minimal residual disease in HCC patients." Cancer Research 83, no. 7_Supplement (April 4, 2023): 1020. http://dx.doi.org/10.1158/1538-7445.am2023-1020.

Full text

Abstract:

Abstract Introduction: Residual disease detection is a significant clinical need in post-surgery treatment of resectable hepatocellular carcinoma (HCC) patients. Previous NGS-based studies targeting fixed genomic regions had reported that circulating tumor DNA (ctDNA) could provide evidence for prognosis prediction during HCC treatment. However, the sensitivity of methods was limited and could not reach the threshold of minimal residual disease (MRD) test. Here we reported a baseline tissue -informed ctDNA NGS assay, detecting MRD in HCC patients who received hepatectomy and predicted prognosis in MRD positive patients. Methods: The study retrospectively enrolled 200 early-stage HCC patients who received surgical resections. Tumor and normal tissue samples were collected respectively through surgery. Plasma samples were collected 7 days or more post-surgery. In the completed pilot study, samples from 17 patients were tested by a baseline tissue-informed MRD assay (PredicineBEACON). Tumor-specific mutations were identified by whole exon sequencing on baseline tumor and normal tissue samples. For each patient, up to 50 mutations were selected through bioinformatics pipelines for personalized MRD panel design, in combination with a fixed panel of 500 tumor actionable hotspots. The post-surgery plasma samples were then tested for MRD with the panel through ultra-deep sequencing(100,000X). Afterward, genomic tumor fraction proportions were calculated. Results: In the completed pilot study, 12 of 17 patients (70.6%) were called MRD positive based on tests of post-surgery plasma. Among MRD positive patients, 3 were identified as MRD risk high (proportion of tumor fraction≥0.1%) and MRD risk of others were moderate (proportion of tumor fraction<0.1%). The tumor fraction proportion of MRD positive patients varied from 0.013% to 17.84% (median 0.042%). The recurrence free survival (RFS) and overall survival (OS) probabilities were significantly correlated with MRD risk: the median RFS of two groups(risk-high vs. risk-moderate) was 10.1 months vs. 57.4 months (p-value<0.001), while the median OS of two groups (risk-high vs. risk-moderate) was 31.2 months vs. 57.4 months(p-value=0.028). Conclusions: Baseline-informed ctDNA NGS assay showed ultra-sensitive capability of MRD detection on early-stage HCC patients, with outstanding positive rate through plasma samples collected 7 days post-surgery. The MRD risk provided significant prognostic evidence for patient survival and disease relapse. Citation Format: Jie Hu, Haoran Tang, Feng Xie, Yue Zhang, Shidong Jia, Jian Zhou. Tissue-informed ctDNA MRD assay detects post-surgery minimal residual disease in HCC patients [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 1020.

APA, Harvard, Vancouver, ISO, and other styles

22

Zhu, Yuelin. "Li Zhang. Xin Zhongguo yu xin ke xue: gao fen zi xue zai xian dai Zhongguo de jian li [New Science for a New China: Institutionalization of Polymer Science in the P. R. China]. (Zhongguo jin xian dai ke xue ji shu shi yan jiu cong shu.). 340 pp., tables, bibl., index. Jinan: Shandong jiao yu chu ban she [Shandong Education Press], 2005. ¥37.50 (paper)." Isis 99, no. 2 (June 2008): 446–47. http://dx.doi.org/10.1086/591385.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Yin, Limei, Wenbo Wang, Zhuoran Yao, Jianxin Xue, Ruizhan Tong, Hui Wang, Shuangsi Liao, et al. "Abstract 5569: CAR-T cells with αPDL1/CD28 switch-receptor synergize radiotherapy and anti-PD1 therapy in solid tumors." Cancer Research 82, no. 12_Supplement (June 15, 2022): 5569. http://dx.doi.org/10.1158/1538-7445.am2022-5569.

Full text

Abstract:

Abstract The therapeutic efficacy of CAR-T cells in solid tumors, unlike in hematologic tumor, is greatly limited by the insufficient infiltration and persistence of CAR-T cells as well as the immunosuppressive tumor microenvironment. The aim of this study was to overcome these obstacles by introducing an αPDL1/CD28 switch-receptor construct and by seeking combinatorial strategies for CAR-T cells in solid tumors. We found that in non-transduction T cells, the cytokine release and T cell proliferation were repressed in response to PD-L1 protein, while T cells that express αPDL1/CD28 switch-receptor showed enhanced functions, indicating that αPDL1/CD28 could revert PD-L1 inhibition into CD28 costimulation. CAR-T cells with αPDL1/CD28 switch-receptor showed better effector function than that of unitary CAR-T in vitro studies and significant responses in tumor-bearing mice, with more effector memory T cells infiltrated in the tumor. On this basis, PD-1 inhibitor can further enhance the efficacy and persistence of αPDL1/CD28 CAR-T cells, especially in PDL1+ tumor models. We found in vitro studies that radiotherapy increased the expression of T-cell recruiting chemokines and promoted CAR-T cell transmigration. In tumor-bearing mice, synergistic anti-tumor efficacy of mice treated with radiotherapy and αPDL1/CD28 CAR-T cells was further observed. Finally, triple therapy with radiotherapy and anti-PD1 plus αPDL1/CD28 CAR-T cells maximized antitumor responses and induced complete cures in the tumor-bearing mice. Our study suggests that αPDL1/CD28 augments the function of CAR-T cells, and the combinatorial regime of αPDL1/CD28 CAR-T cells, radiotherapy and anti-PD1 in solid tumors could be further investigated. Citation Format: Limei Yin, Wenbo Wang, Zhuoran Yao, Jianxin Xue, Ruizhan Tong, Hui Wang, Shuangsi Liao, Laduona Wang, Yue Zheng, Feifei Na, Min Yu, Xuanwei Zhang, Youling Gong, Meijuan Huang, Xianming Mo, Chong Chen, You Lu. CAR-T cells with αPDL1/CD28 switch-receptor synergize radiotherapy and anti-PD1 therapy in solid tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5569.

APA, Harvard, Vancouver, ISO, and other styles

24

Shen, Grace Y. "Zhang Jiuchen . Di zhi xue yu Minguo she hui: 1916–1950 [Geology and Society: A Study in Chinese National Geological Survey]. (Zhongguo jin xian dai ke xue ji shu shi yan jiu cong shu.). 286 pp., bibl., index. Jinan: Shandong jiao yu chu ban she [Shandong Education Press], 2005. π⃑ 33 (paper)." Isis 99, no. 3 (September 2008): 634–35. http://dx.doi.org/10.1086/593257.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Wang, Zuoyue. "Jian Zhang. Ke xue she tuan zai jin dai Zhongguo de ming yun: yi Zhongguo ke xue she wei zhong xin [The Science Association and the Change of Society in Modern China: A Study on the Science Society of China]. (Zhongguo jin xian dai ke xue ji shu shi yan jiu cong shu.). 460 pp., tables, bibl., index. Jinan: Shandong jiao yu chu ban she [Shandong Education Press], 2005. ¥49 (paper)." Isis 99, no. 2 (June 2008): 437–38. http://dx.doi.org/10.1086/591376.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Fang, Li-Zhi. "Jiang Xiaoyuan ;, Wu Yan . Zijin shan tian wen tai shi gao: Zhongguo tian wen xue xian dai hua ge an. [History of Purplemountain Observatory.] (Zhongguo jin xian dai ke xue ji shu shi yan jiu cong shu.). 219 pp., tables, bibl., index. Jinan: Shandong jiao yu chu ban she [Shandong Education Press], 2004. 29 (paper)." Isis 99, no. 3 (September 2008): 645–46. http://dx.doi.org/10.1086/593267.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Chai, Yue, Jiaxuan Liu, Mingxia Jiang, Maiyue He, Xin Wang, Yipeng Wang, Xue Yang, Jing Wang, Binghe Xu, and Qiao Li. "Abstract PO2-18-12: Updated Results of a Phase II Study: Neoadjuvant Inetetamab Combined with Pertuzumab, Paclitaxel and Carboplatin for Locally Advanced HER2-Positive Breast Cancer." Cancer Research 84, no. 9_Supplement (May 2, 2024): PO2–18–12—PO2–18–12. http://dx.doi.org/10.1158/1538-7445.sabcs23-po2-18-12.

Full text

Abstract:

Abstract Background: Inetetamab is a neotype HER2-targeted monoclonal antibody with amino acids modified Fc segment which optimizes the antibody-dependent cellular cytotoxicity effect. However, robust evidence evaluating the combination of inetetamab combined with pertuzumab, paclitaxel and carboplatin (TCbIP) for neoadjuvant therapy is still lacking. This study aimed to evaluate the efficacy and safety of TCbIP as a neoadjuvant therapy for patients with locally advanced HER2-positive breast cancer. We now present the updated results of this trial. Methods: This phase II trial included female patients with histologically confirmed stage IIA to IIIC HER2-positive primary invasive breast cancer. Eligible patients received TCbIP treatment every three weeks for a maximum of six cycles followed by surgery. The primary endpoint was pathologic complete response (pCR, ypT0/is ypN0) rate. Key secondary endpoints included near pCR (npCR, residual breast disease < 1cm) rate, objective response rate (ORR) and safety. Results: From November 2021 to July 2023, 40 patients were enrolled in the trial. One patient received one cycle of the study treatment but was lost to follow-up without surgery, and five patients received one cycle of the study treatment and were still undergoing treatment, leaving 34 patients in the intention-to-treat (ITT) population. Among these 34 patients (82.4% in stage III), 22 patients completed the study treatment and surgery (per-protocol [PP] population) and 12 patients were still undergoing neoadjuvant treatment. The ORR was 91.2% (31/34) in the ITT population and 86.4% (19/22) in the PP population. Among the 22 patients in the PP population, 12 patients (54.5%) achieved pCR, and18 patients (81.8%) achieved npCR. The pCR rates for patients with hormone receptor (HR) negative and positive tumors were 80.0% (8/10) and 33.3% (4/12), respectively. The most common grade 3 adverse event was neutropenia (17.6%). No significant reduction in the left ventricular ejection fraction was observed in any patient. Conclusions: Neoadjuvant therapy with TCbIP demonstrated promising efficacy and manageable toxicity in patients with HER2-positive locally advanced breast cancer. Registration number: NCT05749016 (www.clinicaltrials.gov). Citation Format: Yue Chai, Jiaxuan Liu, Mingxia Jiang, Maiyue He, Xin Wang, Yipeng Wang, Xue Yang, Jing Wang, Binghe Xu, Qiao Li. Updated Results of a Phase II Study: Neoadjuvant Inetetamab Combined with Pertuzumab, Paclitaxel and Carboplatin for Locally Advanced HER2-Positive Breast Cancer [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PO2-18-12.

APA, Harvard, Vancouver, ISO, and other styles

28

Lewis, John W., and Xue Litai. "Jifeng Liu;, Yanqiong Liu;, Haiyan Xie. Liang dan yi xing gong cheng yu da ke xue [The Project of “Two Bombs, One Satellite”: A Model of the Big Science]. (Zhongguo jin xian dai ke xue ji shu shi yan jiu cong shu.). 254 pp., illus., tables, bibl., index. Jinan: Shandong jiao yu chu ban she [Shandong Education Press], 2004. ¥27 (paper)." Isis 99, no. 2 (June 2008): 430–31. http://dx.doi.org/10.1086/591370.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Plebanek, Michael P., Yue Xue, Y.-Van Nguyen, Nicholas C. DeVito, Xueying Wang, Georgia Beasley, Nagendra Yarla, Bala Thievanthiran, and Brent A. Hanks. "Abstract 2892: A SREBF2-dependent genetic program drives a novel immunotolerant dendritic cell population that supports cancer progression." Cancer Research 83, no. 7_Supplement (April 4, 2023): 2892. http://dx.doi.org/10.1158/1538-7445.am2023-2892.

Full text

Abstract:

Abstract The development of immune responses to cancers are crucially dependent upon effective antigen cross-presentation by local dendritic cell (DC) populations. Indeed, DC-mediated T cell stimulation is essential for generating responses to anti-PD-1 immunotherapy. Tumors have been shown to hijack DC function in a process broadly known as tolerization. Despite the significant implications of this process on the modulation of anti-tumor immunity, the underlying mechanisms of this process remain unclear. We have identified a unique population of DCs in transgenic models of both melanoma and non-small cell lung cancer that arise within the tumor microenvironment and migrate to the draining lymph node (LN) tissues during the course of disease progression. RNAseq and flow cytometry studies revealed this DC population to exhibit a unique CD63 surface marker, enabling us to determine this subset to drive regulatory T cell (Treg) and TH2 expansion while suppressing conventional DC-mediated activation of CD8+ T cell responses, even at rare numbers. Additional transcriptional and metabolic studies showed these CD63+ DCs to be a subset of the previously identified 'mature DCs enriched in immunoregulatory molecules' (mregDC) population and to exhibit both enhanced activity of the mevalonate biosynthetic pathway as well as increased lipid stores and dependence on fatty acid oxidation. Inhibitor studies confirmed that mevalonate biosynthesis drives CD63+ mregDC-mediated immune tolerance while scATACseq studies have identified open regulatory elements in CD63+ mregDCs associated with key rate-limiting genes associated with the mevalonate pathway. Additional lineage analysis revealed the CD63+ mregDC population to evolve primarily from type 2 conventional DCs in vivo. Both DC-specific genetic deletion of the SREBF2 master transcription factor as well as SREBP2 pharmacologic inhibition suppresses melanoma progression while enhancing tumor CD8+ T cell infiltration. Adoptive transfer of CD63+ mregDCs enhances melanoma metastases and promotes the accumulation of Tregs in draining LN tissues. scRNAseq studies as well as spatial transcriptomic analysis has confirmed this same DC population in the sentinel LN tissues of melanoma patients. We propose that this novel DC subset represents a key target for augmenting anti-tumor immune responses and suppressing metastatic progression. Ongoing work is focused on dissecting the regulatory pathways dictating the transcriptional program of CD63+ mregDCs and developing a CD11c-CD63 bispecific depletion antibody for further pre-clinical testing. Citation Format: Michael P. Plebanek, Yue Xue, Y-Van Nguyen, Nicholas C. DeVito, Xueying Wang, Georgia Beasley, Nagendra Yarla, Bala Thievanthiran, Brent A. Hanks. A SREBF2-dependent genetic program drives a novel immunotolerant dendritic cell population that supports cancer progression [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 2892.

APA, Harvard, Vancouver, ISO, and other styles

30

Shen, Grace Y. "Xuetong Li. Weng Wenhao nian pu [The Chronicle of Dr. Weng Wenhao]. (Zhongguo jin xian dai ke xue ji shu shi yan jiu cong shu.). 430 pp., bibl., index. Jinan: Shandong jiao yu chu ban she [Shandong Education Press], 2005. π¯16 (paper)." Isis 99, no. 4 (December 2008): 874–75. http://dx.doi.org/10.1086/597736.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Aldersley, Jordan, Michael Liu, Lixing Qi, Ye Jiao, Akuah Kontor, Yue Ke, and Zhaohui Wang. "Abstract 5694: Accurate detection of microsatellite instability (MSI) in matched and unmatched clinical tumor samples using the Pillar oncoReveal MSI panel." Cancer Research 82, no. 12_Supplement (June 15, 2022): 5694. http://dx.doi.org/10.1158/1538-7445.am2022-5694.

Full text

Abstract:

Abstract Introduction: MSI is caused by mutations in mismatch repair (MMR) genes that result in increased insertions and deletions within simple repeats in the genome. The MSI-High (MSI-H) phenotype is prevalent in Lynch Syndrome, caused by the inheritance of MMR loss-of-function alleles as well as in 15% of all colorectal cancers. Accurate, timely detection of MSI is important for predicting the efficacy of immunotherapies that take advantage of increased expression of neoantigens in MSI-H tumors. The Pillar oncoReveal MSI Panel is a targeted NGS assay comprised of a single-tube multiplex PCR-based chemistry and companion Pillar Variant Analysis Toolkit (PiVAT) software with MSIsensor-based detection of tumor MSI status. We report the accuracy of the PiVAT MSI module in detection of tumor MSI status without the need for a matched normal comparator. Methods: 56 pairs of clinical tumor and matched normal FFPE samples were analyzed using the oncoReveal MSI Panel. MSI status was verified by a standard MSI detection method. Illumina sequencing was performed using a PE2x150 protocol. PiVAT determines MSI status using MSIsensor. Call performance on Burrows-Wheeler Alignment (BWA) BAM files was compared with PiVAT’s paired-end assembled and filtered BAM files (PBAM). In both cases coverage normalization and FDR thresholds were set to 1. In a second experiment, 88 clinical normal tissue samples were combined with the matched tumor/normal samples and analyzed using the PiVAT MSI module’s unmatched calling protocol using a synthetic pooled normal. Results: MSI was first assessed in matched tumor/normal samples using MSIsensor. Preliminary analyses revealed a greater separation of MSI scores between MSI-positive and -negative tumors when MSIsensor was run on PBAM vs BWA-generated BAM files. Due to high individual variability at MS sites, MSI detection is difficult for tumor samples with no available matched normal tissue. Hierarchical clustering demonstrated that a subset of MS sites exhibited low variability between normal samples and showed large differences between MSI-H tumor, and MS stable (MSS) tumor and/or normal samples when compared to a pooled normal baseline. Analyses based on the full target set did not accurately detect differences between MSI-H and MSS tumor or normal samples in the pooled normal calling context. When using a clustered subset of sites, MSI-detection was comparable with the matched tumor/normal context. Conclusions: We developed a robust assay for MSI detection in multiple tumor types that encompasses library generation, data analysis, and diagnosis with 97% sensitivity and 100% specificity. We also demonstrate that accurate MSI-detection is possible in the absence of matched normal tissue, using a pooled normal reference and a curated target set. Citation Format: Jordan Aldersley, Michael Liu, Lixing Qi, Ye Jiao, Akuah Kontor, Yue Ke, Zhaohui Wang. Accurate detection of microsatellite instability (MSI) in matched and unmatched clinical tumor samples using the Pillar oncoReveal MSI panel [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5694.

APA, Harvard, Vancouver, ISO, and other styles

32

Hu, Jia, Jun Ni, Longxian Jiao, Jinghong Zhou, Shiming Fan, Renxiang Tang, Wei Zhang, et al. "Abstract 6321: HMPL-453, a highly selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays potent activity in FGFR-altered tumor models." Cancer Research 83, no. 7_Supplement (April 4, 2023): 6321. http://dx.doi.org/10.1158/1538-7445.am2023-6321.

Full text

Abstract:

Abstract Background: Fibroblast growth factors (FGFs) and their receptors (FGFRs) regulate numerous cellular processes. Dysregulation of FGFR signaling due to receptor fusion, mutation or amplification is observed across multiple cancer types, making activated FGFRs an important therapeutic target. Herein, we present the preclinical characterization of HMPL-453, a highly potent and selective inhibitor of FGFR1, 2, and 3, discovered and being currently developed in phase II clinical trial (NCT04353375) by HUTCHMED. Methods: Kinase activity was measured by Transcreener™ Fluorescence Polarization assay or Z’-LYTE kinase assay. In vitro anti-proliferation activity was measured by CellTiter-Glo luminescent or CCK-8 assay. The effect of HMPL-453 on FGFR signaling pathway was detected by western blot. Multiple tumor models with FGFR alteration were applied in Nu/Nu nude mice to determine anti-tumor efficacy of 453 as a single agent. A model in immune-competent BALB/c mice inoculated with the constructed NIH/3T3 cells carrying FGFR2-AHCYL1 fusion was chosen to investigate the combination effect of HMPL-453 with anti-PD-1 antibody. Results: HMPL-453 potently inhibited the tyrosine kinase activities of recombinant FGFR 1, 2, and 3 in vitro (IC50 values of 6, 4, and 6 nM, respectively) with weaker activity against FGFR4 (IC50 = 425 nM). HMPL-453 selectively inhibited proliferation of tumor cell lines with dysregulated FGFR signaling (GI50s: 3~105 nM) compared with cell lines lacking FGFR aberrations (GI50s > 1.5 µM). HMPL-453 demonstrated strong inhibition of phosphorylation of FGFR and downstream protein in tumor cell lines harboring FGFR2 fusion. Oral administration of HMPL-453 could induce time- and dose-dependent inhibition of phosphorylation of FGFR and resulted in remarkable and dose-dependent anti-tumor activity in multiple FGFR-altered tumor models. HMPL-453 at the dose of 50 mg/kg/day could induce tumor regression in most tumor models tested. Moreover, HMPL-453 significantly improved anti-tumor activity of anti-PD-1 antibody in a FGFR2 fusion model by priming the immune environment. Conclusion: HMPL-453 is a highly potent and selective inhibitor of FGFR 1, 2, and 3 with strong activity against FGFR-deregulated tumors in preclinical models, supporting continued investigation in patients with FGFR alterations (such as fusion and mutation) either as a single agent or in combination with PD-1 blockade. Citation Format: Jia Hu, Jun Ni, Longxian Jiao, Jinghong Zhou, Shiming Fan, Renxiang Tang, Wei Zhang, Xuelei Ge, Qihang Zhang, Juntao Yu, Ying Yu, Dongxia Shi, Min Cheng, Weifang Xue, Sumei Xia, Zeyu Zhong, Jian Wang, Yang Sai, Weiguo Qing, Guangxiu Dai, Yongxin Ren, Michael Shi, Weiguo Su. HMPL-453, a highly selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays potent activity in FGFR-altered tumor models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 6321.

APA, Harvard, Vancouver, ISO, and other styles

33

Shao, Shuai, Shan Tang, Xue Wu, Yue Zhao, Huo Yang, Lijun Cheng, and Lang Li. "Abstract LB131: Genome-wide CRISPR-Cas9 screen parallel with transcriptome RNAseq to identify synthetic lethal drug targets to cisplatin/doxorubicin in triple-negative breast cancer." Cancer Research 82, no. 12_Supplement (June 15, 2022): LB131. http://dx.doi.org/10.1158/1538-7445.am2022-lb131.

Full text

Abstract:

Abstract Triple-negative breast cancer (TNBC) accounts for 15-20% of cases yet disproportional accounts for 35% of breast cancer deaths. Chemotherapy remains the first-line treatment for TNBC. Despite the great research efforts, above half of TNBC patients have developed drug resistance after chemotherapies. Thus, the study of chemo-resistance and identification of novel targets are critical to improving TNBC treatment. In our study, we compared genomic profiles between TNBC cell lines and patients' samples and selected the most representative one, MDA-MB-231,for TNBC chemotherapy-poor responders. Then, Genome-wide CRISPR-Cas9 screen and RNAseq were performed in MDA-MB-231 to identify potential synthetic lethal targets to Cisplatin/Doxorubicin. To identify cell lines that correspond to poor responder patients, we selected genomic profiles of 17 good responders, 36 poor responders, and 21 TNBC cell lines from GEO database. We used Hierarchical clustering analysis, Spearman's rank correlation, and GSEA analysis to determine the representative cell lines in gene expression level and pathway level. With the results from our analysis, MDA-MB-231 is most representative among 21 TNBC cell lines. To identify essential genes and pathways for cell survival under Cisplatin/Doxorubicin treatment, we performed genome-wide CRISPR-Cas9 knockout screens in MDA-MB-231 and introduced CRISPR library TKOV3 into cells by lentivirus. After puromycin selection, the surviving cells were treated with Cisplatin/Doxorubicin for 21 days and sgRNAs were sequenced at ~80 million reads per sample to achieve a 600x coverage over the TKOV3 library. To accurate the CRISPR-Cas9 screen results and capture the transcriptomic changes during the Cisplatin/Doxorubicin treatment, we performed RNAseq from MDA-MD-231 after treating in same drug conditions matched with the CRISPR screen. By the MAGeCK algorithm, we generated the list of candidate genes that can form a synthetic lethal partnership with Cisplatin/Doxorubicin. Our negative selection screen confirmed that loss of essential genes from DNA damage repair and regulation of DNA replication pathways, such as BCL2L1, ATM, CDC25B, NBN, sensitizes cells to Cisplatin/Doxorubicin, which has been reported in DNA damage drug synthetic lethal studies. Meanwhile, our analysis also revealed hundreds of unrecognized genes involved in the G2/M DNA damage checkpoint, AMPK signaling pathway, mTOR signaling pathway, and Hsp90-mediated pathways. In addition, the pathways related to transcriptomic response to Cisplatin/Doxorubicin from RNAseq data show many differences with essential pathways shown in the CRISPR screen, which proposed a complex regulation system in cell response to DNA damage drug. In general, Genome-wide CRISPR-Cas9 screen along with transcriptome RNAseq is efficient to identify essential genes that have potential synthetic lethal interaction with Cisplatin/Doxorubicin. This provides new opportunities for combination therapies in TNBC chemo-resistant patients. Citation Format: Shuai Shao, Shan Tang, Xue Wu, Yue Zhao, Huo Yang, Lijun Cheng, Lang Li. Genome-wide CRISPR-Cas9 screen parallel with transcriptome RNAseq to identify synthetic lethal drug targets to cisplatin/doxorubicin in triple-negative breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr LB131.

APA, Harvard, Vancouver, ISO, and other styles

34

Xue, Jie, Keyu Li, Poonam Yakkundi, Palak Chadasama, Tina Mao, Zee Malik, Vidhya Rao, et al. "Abstract 6726: Costimulatory IgM T-cell engagers with enhanced and durable cytotoxicity." Cancer Research 84, no. 6_Supplement (March 22, 2024): 6726. http://dx.doi.org/10.1158/1538-7445.am2024-6726.

Full text

Abstract:

Abstract T-cell engagers (TCEs) have established therapeutic effect in treatment of various cancers by harnessing the power of the immune system against tumors in a targeted manner. IgM-based TCEs may offer high avidity, specificity, and safety advantages over other modalities because of their multivalent architecture and unique positioning of the CD3 binding domain on the J-chain. We have built a costimulatory IgM TCE platform that engages both signal 1 and signal 2 on T-cells, with the goal of enabling their optimal activation and survival for more robust and durable cytotoxic activity. Multiple antigen targeting costimulatory IgM TCEs were generated and activity was evaluated both in vitro and in vivo to assess the role of CD28 co-stimulation. Costimulatory IgM TCEs engaged both CD3 and CD28 on the T-cell surface, enhancing in vitro cytotoxicity and T-cell activation. Levels of IL-2 increased significantly with dual signal engagement promoting proliferation and survival of T-cells. In long-term culture assays, costimulatory IgM TCEs promoted better T-cell proliferation and survival compared to IgM TCEs with only a CD3 binder, and was even more pronounced at low E:T ratios. In the absence of CD3 engagement, CD28 binding alone did not induce any T-cell activation, cytotoxicity, or cytokines. Activation of T-cells was also fully dependent on the presence of target cells, underscoring the safety profile of the platform. In Hu-PBMC xenograft tumor models, costimulatory IgM TCEs exhibited stronger in vivo anti-tumor activity compared to TCEs only engaging CD3. Tumor growth inhibition was maintained for longer after dosing was stopped with costimulatory IgM TCEs, indicating the durability of responses. Costimulatory IgM TCEs suppressed tumor growth in xenograft studies using cell lines that expressed both high and low target copy numbers suggestive of their broad utility against multiple tumor types. Enhanced in vivo anti-tumor activity of costimulatory IgM TCEs was associated with significant increases in intra-tumoral CD8/CD3+T-cells.Both peripheral and intra-tumoral T-cells exhibited enhanced anti-apoptotic and cytotoxic phenotypes indicative of the costimulatory activation. IgM-based costimulatory TCEs provide enhanced cytotoxicity through optimal T-cell activation and proliferation/survival. This dual engagement of T-cell activation signals, along with the high avidity target binding offered by IgM platform, could enable the creation of effective therapeutics targeting pathogenic cells in autoimmune diseases and solid tumors that will maintain activity even in conditions with low T-cell counts. Citation Format: Jie Xue, Keyu Li, Poonam Yakkundi, Palak Chadasama, Tina Mao, Zee Malik, Vidhya Rao, Madhura Joglekar, Kristene Mai, Gene Li, Deepal Pandya, Rodnie Rosete, Zhongde Ye, Leyla Tahrani, Jinqiu Wang, Nardeen Hanna, Elizabeth Perez, Yue Wang, Sachi Ahmed, Lusiana Widjaja, Paul Hinton, Krzysztof Bzymek, Bruce Keyt, Miho Oyasu, Liqin Liu, Angus Sinclair, Umesh S. Muchhal. Costimulatory IgM T-cell engagers with enhanced and durable cytotoxicity [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 6726.

APA, Harvard, Vancouver, ISO, and other styles

35

Meng, Yue. "Weija Hu. Selected Materials on the Science and Technology in the People's Republic of China (1949–1995). (Zhongguo jin xian dai ke xue ji shu shi yan jiu cong shu.) 381 pp., bibl., index. Jinan: Shandong jiao yu chu ban she [Shandong Education Press], 2006. π¯120 (paper)." Isis 99, no. 4 (December 2008): 872–73. http://dx.doi.org/10.1086/597734.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Chu, Pingyi. "Anjing Qu. Zhongguo jin xian dai ke ji jiang li zhi du [Science and Technology Awards in Modern China]. (Zhongguo jin xian dai ke xue ji shu shi yan jiu cong shu.). 329 pp., tables, bibl., index. Jinan: Shandong jiao yu chu ban she [Shandong Education Press], 2005. (Paper.)." Isis 99, no. 2 (June 2008): 444–45. http://dx.doi.org/10.1086/591383.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Zhao, Dongni, Shaohua Zhang, Chun Lin, Jiefeng Ye, Yue Chen, Jian-Min Zhang, Jianmin Tao, et al. "Covalent Heterojunctions Enhance Bi₂S₃/Reduced Graphene Oxide (rGO) Nanocomposite Performance as Aqueous Zinc Ion Battery Material." ECS Meeting Abstracts MA2023-01, no. 4 (August 28, 2023): 837. http://dx.doi.org/10.1149/ma2023-014837mtgabs.

Full text

Abstract:

The shortage of lithium resources, safety and recycling difficulty has focused attention on alternative energy storage devices in recent years. The aqueous zinc-ion battery (ZIB) stands out against such a background because of its earth abundance, safety, and environmental friendliness.1 However, the limited choice of cathode materials hinders the development of advanced high-energy-density aqueous ZIBs. At present, manganese oxide2 and vanadium oxide3 are the two most widely studied zinc-ion battery cathodes, but the migration of Zn2+ in these materials is limited by the strong electrostatic interaction with lattice oxygen ions, resulting in poor reversible capacity. Metal sulfides, instead, may effectively improve the electrochemical performance reversibility of ZIBs. Layered metal sulfides have been extensively studied in monovalent cation (Li+, Na+, K+) rechargeable batteries.4 However, although limited studies with Bi2S3 5,6 as ZIB cathode material exist, their detailed electrochemical charge storage and transfer mechanisms are not well understood. In this work, we explore the effect of covalent anchoring Bi2S3 on reduced graphene oxide (rGO) on the stability and cycling performance as a cathode for aqueous ZIBs. During the hydrothermal synthesis, the reduced graphene oxide serves as the nucleation substrate enabling the formation of fine and uniformly sized Bi2S3 grains, Figure 1 (a). Raman and X-ray photoelectron spectroscopy (XPS) confirm the formation of Bi-O-C heterojunctions during hydrothermal synthesis. These oxygen bridges serve as efficient electron transfer channels in the Bi2S3/rGO composite for rapid charge compensation during Zn2+ incorporation/extraction. As a result, Bi2S3/rGO composite shows notably better rate performance and cycling stability compared with pristine Bi2S3. The specific capacity of Bi2S3-rGO8 composite is ~186 mAh g-1 at the current density of 500 mA g-1 after 150 cycles, considerably higher than unsupported Bi2S3. Additionally, the Bi2S3 nucleated on GO with smaller particle sizes can shorten the transport path of zinc ions, which is beneficial for fast charge transfer. Therefore, Bi2S3-rGO8 can deliver more than 100 mAh g-1 at 10 A/g charge/discharge current density, Figure 1 (b). Also, the zinc storage mechanism was analyzed by X-ray diffraction spectroscopy (XRD) and XPS, indicating a reversible conversion reaction of Zn2+ in the Bi2S3-rGO framework. During discharging, Zn2+ is embedded in Bi2S3-rGO frame to form ZnS and Bi wrapped in rGO. The process is accompanied by the dissolution of bismuth into electrolyte and the formation of (ZnSO4)[Zn(OH)2]3·5H2O (ZHS) on the electrode surface. Inhibition of these two processes may further increase the cycle stability of Bi2S3-rGO. Rotating ring disc electrode (RRDE) measurements, in which we detect dissolved Bi, indicate that Bi dissolution in the electrolyte during charging/discharging is mitigated in Bi2S3/rGO electrode, compared to pristine Bi2S3. References: Z. Li, L. Wu, S. Dong, T. Xu, S. Li, Y. An, J. Jiang and X. Zhang, Adv. Funct. Mater., 2021, 31, 2006495. J. Long, Z. Yang, F. Yang, J. Cuan and J. Wu, Electrochim. Acta, 2020, 344, 136155. Wu, Y. Ding, L. Hu, X. Zhang, Y. Huang and S. Chen, Mater. Lett., 2020, 277, 128268. Z. Hu, Q. Liu, S. Chou and S. Dou, Adv. Mater., 2017, 29, 1700606. S. Li, Y. Liu, X. Zhao, K. Cui, Q. Shen, P. Li, X. Qu and L. Jiao, Angew. Chem., Int. Ed., 2021, 60, 20286–20293. T. Xiong, Y. Wang, B. Yin, W. Shi, W. S. V. Lee and J. Xue, Nano-Micro Lett., 2020, 12, 8. Figure 1

APA, Harvard, Vancouver, ISO, and other styles

38

Lewis, John W., and Xue Litai. "Li Chengzhi. A Draft History of Space Technology in China [Zhongguo hangtian jishu fazhan shi gao]. (Zhongguo jin xian dai ke xue ji shu shi yan jiu cong shu.) 3 volumes. 939 pp., illus., tables, bibl., index. Jinan: Shandong Education Press [Shandong jiao yu chu ban she], 2006. ¥106 (paper)." Isis 101, no. 3 (September 2010): 677–78. http://dx.doi.org/10.1086/657225.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Fan, Fa-ti. "Zonggang Hu. Jingsheng sheng wu diao cha suo shi gao [Historical manuscript of Fan Memorial Institute of Biology]. (Zhongguo jin xian dai ke xue ji shu shi yan jiu cong shu.). 250 pp., illus., figs., tables, bibl., index. Jinan: Shangdong jiao yu chu ban she [Shandong Education Press], 2005. 29 yuan (paper)." Isis 99, no. 1 (March 2008): 214. http://dx.doi.org/10.1086/589390.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Minehan, Bridie Andrews. "Zhang Daqing. Zhongguo jin dai ji bing she hui shi [A Social History of Diseases in Modern China (1912–1937)]. (Zhongguo jin xian dai ke xue ji shu shi yan jiu cong shu.) iv + 229 pp., illus., tables, bibl., index. Jinan: Shandong jiao yu chu ban she [Shandong Education Press], 2006. (Paper.)." Isis 100, no. 1 (March 2009): 192–93. http://dx.doi.org/10.1086/599688.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Li, Shang‐Jen. "Guihan Luo. Jin dai xi fang shi Hua sheng wu shi [History of Western Botanical and Zoological Studies in China]. (Zhongguo jin xian dai ke xue ji shu shi yan jiu cong shu.). 434 pp., illus., tables, bibl., index. Jinan: Shandong jiao yu chu ban she [Shandong Education Press], 2005. ¥46 (paper)." Isis 99, no. 2 (June 2008): 380–81. http://dx.doi.org/10.1086/591325.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Chen, Xiang. "Zengjian Guan et alia. Zhongguo jin xian dai ji liang shi gao [A Draft of the History of Modern and Contemporary Metrology in China]. (Zhongguo jin xian dai ke xue ji shu shi yan jiu cong shu.) 258 pp., tables, bibl., index. Jinan: Shandong jiao yu chu ban she [Shandong Education Press], 2005. ¥30.50 (paper)." Isis 100, no. 2 (June 2009): 389–90. http://dx.doi.org/10.1086/605226.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

羅秀美, 羅秀美. "文化記憶的追尋與再現：以「故宮文學家」作品中的「北溝故宮」書寫為主." 中正漢學研究 34, no. 34 (December 2019): 149–84. http://dx.doi.org/10.53106/2306036020191200340006.

Full text

Abstract:

1949年後北京故宮輾轉播遷至臺灣，落腳於臺中霧峰北溝(1950-1965)十六年。守護者莊嚴全家也落腳於此，此地乃當時臺中最重要的文化及旅遊勝地。然1965年北溝故宮北遷後，空餘庫房山洞供人憑弔。當時曾出現一批「故宮文學家」，他們與「北溝故宮」有或深或淺的關係，曾留下相關記憶的書寫，這些文本正是本論文考察的對象。職是，本論文以文化空間與文學記憶為論述概念，首論偏安北溝的「回憶空間」，莊嚴父子大半生與故宮文物流離至北溝所構建的回憶空間。其次則論在此文化空間的文人對傳統文化的傳承，即孔德成與臺靜農等人至北溝故宮清點文物的記憶。第三則論及個體記憶的再現，以臺靜農與林文月、凌叔華與蘇雪林的北溝旅行為主。第四則論及集體記憶中的文化旅遊勝地，兼論齊邦媛的英譯暨陪訪史。透過以上討論，可在集體的歷史大敘述外，呈現個體的文學記憶，豐富北溝故宮之文化記憶。  After 1949, the Palace Museum from Beijing relocated to Taiwan and settled in Beigou北溝 of Taichung (1950-1965) for 16 years. Zhuang Yan莊嚴 and his family who guard the Palace Museum in Beigou北溝故宮 is also setteled here, this place also was the most important cultural tourist attraction in Taichung.However, after the Palace Museum in Beigou北溝故宮 moved northward in 1965, the empty warehouse caves in this area were for people to hang. At that time, a group of " the Palace Museum writers故宮文學家" appeared. They had a deep or shallow relationship with the " the Palace Museum in Beigou北溝故宮",they had left relevant memory writing,these texts are the objects of this paper. In this paper, the concept of cultural space and literary memory is discussed in this dissertation. Firstly, discussion is about the “memory space” in Beigou北溝,the memory space constructed by the Zhuang Yan莊嚴 father and son for most of his life and the Palace Museum 故宮’s cultural relics moved to Beigou北溝. Secondly, it discusses the inheritance of traditional culture by the literati in this cultural space, that is, the memory of Kung Te-Cheng孔德成 and Tai Jing-nong臺靜農 and others to the Palace Museum in Beigou北溝故宮 to count the cultural relics. Thirdly, on the reappearance of personal memory, mainly on the the Palace Museum in Beigou北溝故宮 trip of Tai Jing-nong臺靜農 and Lin Wen-yue林文月, Ling Shu-hua凌叔華and Su Xue-lin蘇雪林. Fourthly, the cultural tourism resort in the collective memory, as well as the history of Qi Bang-yuan’s齊邦媛English translation and accompanying visits. Through the above-mentioned discussion, the individual’s literary memory can be presented in addition to the collective grand historical narrative, especially enrich the cultural memory of the Palace Museum in Beigou北溝故宮.

APA, Harvard, Vancouver, ISO, and other styles

44

Chung, Juliette Yuehtsen. "Bo Liang. Ji shu yu di guo yi yan jiu: riben zai Zhongguo de zhi min ke yan ji gou [Researches on Technology and Imperialism: Japanese Colonial Scientific Research Institutes in China]. (Zhongguo jin xian dai ke xue ji shu shi yan jiu cong shu.). 345 pp., figs., tables, bibl., index. Jinan: Shandong jiao yu chu ban she [Shandong Education Press], 2006. ¥38 (paper).Jianping Han;, Xingsui Cao;, Liwei Wu. Ri wei shi qi de zhi min di ke yan ji gou: li shi yu wen xian [Colonial Scientific Institutions during the Japanese Occupation and Puppet Manchukuo Period: History and Literature]. (Zhongguo jin xian dai ke xue ji shu shi yan jiu cong shu.). 468 pp., figs., bibl., index. Jinan: Shandong jiao yu chu ban she [Shandong Education Press], 2006. ¥49 (paper)." Isis 99, no. 2 (June 2008): 429–30. http://dx.doi.org/10.1086/591369.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Chen, Fuping, David Wei Zhang, Xiongfei Wei, Xiaoyan Zhang, Feng Liu, Sally Ann Henry, Haibo Hu, et al. "(Digital Presentation) Research on Single Wafer RCA Clean in High Aspect Ratio Trenches." ECS Meeting Abstracts MA2022-01, no. 28 (July 7, 2022): 1257. http://dx.doi.org/10.1149/ma2022-01281257mtgabs.

Full text

Abstract:

I ntroduction. High aspect ratio (AR) processes are widely used in front end of line (FEOL) IC manufacturing. Figure 1 depicts high (AR) trench cleaning process. Polymerization residues produced during the dry etch process will cause many problems such as STI voids in the follow-up process if the residues are not removed. This can lead to lower yield and reduction of chip life[1]. It is difficult to completely clean the residue inside trench with aspect ratio greater than 10. As shown in Figure.2, poor wetting of the liquid in the high AR trench, prevents the cleaning of the whole trench. Typically, the wafer surface can be easily cleaned, however residues remain inside of the trench. The cleaning of polymerization residues inside the trench and eliminating watermarks are the main issues in high (AR) cleaning processes. In this paper, we design an infiltration experiment, polymerization residues cleaning experiment and drying experiment to verify single wafer RCA clean performance on high (AR) trench processes. The verification of the single wafer RCA wafer clean is through yield data. Experimental. In the infiltration experiment, a layer of 500A SiO2 was grown on the high aspect ratios trench wafer. As shown in Table I, This was followed by treating the wafers with different process conditions on ACM single wafer tool. The remaining oxide thickness inside trench was measured by transmission electron microscope (TEM). Figure 3 shows experimental steps. In the polymerization residue cleaning experiment, 7 wafers with trenches after dry etching were treated with different chemical and process mode shown in Table II on ACM single wafer tool. The defect count was measured by the inline defect detection equipment and the scanning electron microscope.(SEM) In the drying experiment, high AR wafers were processed on an ACM single wafer tool, under different drying conditions. The trench wafer were then transferred into a vacuum bag and the air was evacuated. If there is no watermark on wafer surface within 15 minutes, we consider that the wafer has been dried in the macro level. Wafers were split between being cleaned by single wafer RCA clean and by bench RCA clean. The wafers are scanned for defect count on the wafer surface after the cleaning process for both the base line (bench) and the single wafer tool. Finally, we review yield on device completion to check results of single wafer and bench clean. Results. Table I shows the result of dHF infiltration experiment. When the pre rinse DIW time exceeds 30 seconds, the whole trench is soaked by DIW, allowing the dHF to permeate the whole trench, with oxide loss being similar from the top to the bottom of the trench. Table II shows the result of cleaning experiment. ACM Single wafer dHF+SC1 (mega) process can effectively clean the whole trench. Figure 4 and 5 shows defect map and SEM picture after single DHF+SC1(mega). Figure 6 shows the effect of chuck rotation speed and N2 flow rate on wafer drying. Figure 10 shows particle performance under different drying process conditions. Figure 7 shows the inline defect map and SEM after dry process. Figure 8 & 9 show the particle performance after the clean process. No special particle map appears with the single wafer clean process. Fig 10 shows the yield performance after all of the processes are completed. Average yield of single clean process is better than the baseline bench clean process. Table 3 shows detailed yield data from the wafer splits . Conclusion. Infiltration and cleaning experiment result shows that single wafer RCA clean can effectively clean the polymerization residues inside of high aspect ratio trenches. Dry experiment result shows that single wafer process can reduce watermark and particles in the dry step. Inline particle performance and final yield performance shows that single wafer RCA clean is better than baseline bench. Single wafer clean has lower standard deviation than bench clean and SW RCA clean in high (AR) trench process is feasible and effective. References. Xue. Research on High Aspect Ratio TSV Cleaning Technology enhanced by Megasonic[D]. Beijing: University of Chinese Academy of Sciences, 2016. JiHoon Cha, ChangSup Mun, etal. Low Si recess on cleaning process by dilute HF/SC-1 with megasonic[J]. Solid State Phenomena, 2008, 134:209-212. H Wang, Yue Ma, Fuping.Chen, etal. Removal of Fine Particle using SAPS Technology and Functional Water[J]. Solid State Phenomena, 2013, 195:185-190. Dae-Hong EOM, Geun-Bae LIM, etal. Reaction of Ozone and H2O2 in NH4OH Solutionsand Their Reaction with Silicon Wafers[J]. Japanese Journal of Applied Physics, 2004, 43:3335-3339. Figure 1

APA, Harvard, Vancouver, ISO, and other styles

46

Schmalzer, Sigrid. "Weimin Xiong;, Kedi Wang. He cheng yi ge dan bai zhi: Jie jing niu yi dao su de ren gong quan he cheng [Synthesize a protein: The story of total synthesis of crystalline insulin project in China]. (Zhongguo jin xian dai ke xue ji shu shi yan jiu cong shu.). 194 pp., figs., bibl., app., index. Jinan: Shandong jiao yu chu ban she [Shandong Education Press], 2005. $25 (paper)." Isis 99, no. 1 (March 2008): 231–32. http://dx.doi.org/10.1086/589404.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

James, Nicole, Melih Ozsoy, Payton De La Cruz, Morgan Woodman, and Jennifer Ribeiro. "729 Immunologic tumor cell intrinsic effects of standard of care therapies for ovarian cancer." Journal for ImmunoTherapy of Cancer 9, Suppl 2 (November 2021): A758. http://dx.doi.org/10.1136/jitc-2021-sitc2021.729.

Full text

Abstract:

BackgroundOutcomes for high grade serous ovarian cancer (HGSOC) patients have remained dismal due to the inevitable development of chemotherapy resistance with recurrent disease.1 In order to better tailor treatment approaches and uncover opportunities for novel treatments, we need to better understand factors contributing to chemotherapy resistance. Recent studies have shown that immune-related gene expression profiles may serve as prognostic indicators of response to chemotherapy and clinical outcomes in solid tumors, including ovarian cancer.2–7 Moreover, immunologic factors have been shown to mediate chemotherapy resistance8 Reports in the literature show that common ovarian cancer therapeutics, including chemotherapy, PARP inhibitors, and bevacizumab, modulate tumor cell expressed PD-L1 levels through immunologic signaling pathways.9–12 However, very little research has addressed the effect of these treatments on other immune ligands or the differences in immunologic responses between platinum-sensitive and platinum-resistant HGSOC cell lines.MethodsThe HGSOC cell lines OVCAR4 (naturally platinum-resistant), PEO1 and PEO4 (matched platinum-sensitive and -resistant lines from the same patient), were treated with common ovarian cancer therapeutics (carboplatin/paclitaxel, olaparib, and bevacizumab), in the presence or absence of peripheral blood mononuclear cells. Western blot was employed to identify levels of immune ligands of interest and a proteome profiler was used to detect broad immunologic changes in response to standard of care therapeutics.ResultsOlaparib and bevacizumab treatment strikingly upregulated levels of tumor cell expressed immune ligands ICOSL and PVRL2. Platinum status or presence of an immune component had no bearing on the effect. Moreover, blockade of PVRL2 using siRNA or monoclonal antibodies suppressed STAT3 signaling. When examining the effect of these therapeutics on cytokine levels in HGSOC cell lines treated in immune cell co-culture, OVCAR4 cells displayed marked changes in cytokine levels, particularly CXCL10, CXCL12, SERPINE1, IL1A, and IL1RA. While PEO1 and PEO4 cells displayed more subtle cytokine changes compared to OVCAR4 cells, differences in basal levels and treatment responses were observed between the platinum-sensitive and -resistant lines, most strikingly higher basal levels of SERPINE1 and CCL5/RANTES in PEO4 cells, and a robust increase in IL8 levels in response to chemotherapy in only PEO1 cells and not PEO4.ConclusionsIn conclusion, common ovarian cancer chemotherapeutics and targeted agents induce tumor cell intrinsic immunologic effects that could potentially be exploited as combinatorial therapeutic targets. Differences in immunologic responses may help define platinum-sensitive and -resistant disease. These results will require further exploration in immune-competent mouse models and human HGSOC tissue.ReferencesCortez AJ, Tudrej P, Kujawa KA, Lisowska KM. Advances in ovarian cancer therapy. Cancer Chemother Pharmacol 2018;81(1):17–38.James NE, Miller K, LaFranzo N, Lips E, Woodman M, Ou J, Ribeiro JR. Immune modeling analysis reveals immunologic signatures associated with improved outcomes in high grade serous ovarian cancer. Front Oncol 2021;11:622182.Liu R, Hu R, Zeng Y, Zhang W, Zhou H-H. Tumour immune cell infiltration and survival after platinum-based chemotherapy in high-grade serous ovarian cancer subtypes: a gene expression-based computational study. EBioMedicine 2020;51:102602.Liu J, Meng H, Nie S, Sun Y, Jiang P, Li S, et al. Identification of a prognostic signature of epithelial ovarian cancer based on tumor immune microenvironment exploration. Genomics. 2020.Ding J, Zhang Q, Chen S, Huang H, He L. Construction of a new tumor immunity-related signature to assess and classify the prognostic risk of ovarian cancer. Aging (Albany, NY). 2020;12.Wu Y, Xia L, Zhao P, Deng Y, Guo Q, Zhu J, et al. Immune profiling reveals prognostic genes in high-grade serous ovarian cancer. Aging (Albany, NY). 2020;12(12):11398–11415.Montfort A, Owen S, Piskorz AM, Supernat A, Moore L, Al-Khalidi S, et al. Combining measures of immune infiltration shows additive effect on survival prediction in high-grade serous ovarian carcinoma. Br J Cancer 2020;122(12):1803–1810.Liu W, Wang Y, Xie Y, Dai T, Fan M, Lu C, Zou Y. Cisplatin remodels the tumor immune microenvironment via the transcription factor EB in ovarian cancer. Cell Death Discov. 2021;7(1):136.Peng J, Hamanishi J, Matsumura N, Abiko K, Murat K, Baba T, Yamaguchi K, Horikawa N, Hosoe Y, Murphy SK, Konishi I, Mandai M. Chemotherapy induces programmed cell death-Ligand 1 overexpression via the nuclear factor-κB to foster an immunosuppressive tumor microenvironment in Ovarian cancer. Cancer Res 2015;75(23):5034–45.Jiao S, Xia W, Yamaguchi H, Wei Y, Chen M-K, Hsu J-M, et al. PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression. Clin Cancer Res 2017;23(14):3711–3720.Xue C, Xu Y, Ye W, Xie Q, Gao H, Xu B, et al. Expression of PD-L1 in ovarian cancer and its synergistic antitumor effect with PARP inhibitor. Gynecol Oncol 2020;157(1):222–233.Zhang L, Chen Y, Li F, Bao L, Liu W. Atezolizumab and bevacizumab attenuate cisplatin resistant Ovarian cancer cells progression synergistically via suppressing epithelial-Mesenchymal transition. Front Immunol 2019;10:867.

APA, Harvard, Vancouver, ISO, and other styles

48

Li (李林), Lin. "Teaching as Learning: Etymological Investigation, Canonical Analysis, and Experiential Reflection in the Chinese Cultural Context." ECNU Review of Education, August 3, 2023. http://dx.doi.org/10.1177/20965311231189524.

Full text

Abstract:

Purpose This study re-examines the relationship between jiao (lit. teaching) and xue (lit. learning)—the foundational education concepts in the traditional Chinese cultural context—to enlighten our contemporary understandings of education and educational research. Design/Approach/Methods This study first lays its foundation on an etymological investigation. It then integrates two mutually connected approaches— the classics and the self as method—to present a comprehensive analysis. Finally, it critically reviews the methodology used in this study. Findings The interdependency of xue and jiao has an etymological foundation, supported by canonical doctrines and verified by individualized experiences. The interpretation of xue as xiao (to imitate) describes the origin and process of education in which the junior imitated and followed the elder, while the extended interpretation of xue as jue (to awaken) stresses the effects and functions of education. In the classical Chinese context, greater significance was placed on xue—the keyword concurrently connoting the meaning of teaching and learning in the modern sense. It is misleading to narrowly render the originally meaningful word group xuexi as learning in modern English. Originality/Value This study consults sources in multiple languages and integrates both the classics and the self as method. Based on this, the etymological investigation, canonical analysis, and experiential reflection are collated to provide a rich and deep discussion. By focusing on the core characteristics and the concepts they imply, this study also touches on the key characteristics of the hieroglyphic system and the unique way of thinking it represents.

APA, Harvard, Vancouver, ISO, and other styles

49

Cruveillé, Solange. "Da Xie 大解, Zhu Yue 朱岳, Can Xue 残雪." Impressions d’Extrême-Orient, no. 8 (December 30, 2018). http://dx.doi.org/10.4000/ideo.1006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

謝, 永芳. "近世廣東詞社考論." 人文中國學報, September 1, 2009, 293–310. http://dx.doi.org/10.24112/sinohumanitas.152570.

Full text

Abstract:

LANGUAGE NOTE | Document text in Chinese; abstract also in English. 近世廣東詞壇至少存在過越臺、花田、訶林、山堂、風餘等六個詞社。綜合相關詞集序跋、方志、詞作題序和自注等文獻資料，可以從結社緣起、組成人員、存在時間、集會地點、雅集次數、唱酬情形等方面考知這六個詞社的大概情形。近世廣東詞社的出現，是粤東詞學發展内在的規律、粵東文壇傳統的結社之風的影響、時局的劇變、詞人群體意識的逐漸增强以及存在一個以血緣、里籍和師友關係凝聚起來的龐大詞學網絡等使然。近世廣東詞社是近世廣東詞壇詞體創作繁榮興旺的重要表徵，考察和討論近世廣東詞社及其興廢與詞史意義，可以爲全面勾畫和深刻洞悉近世廣東詞史提供幫助。Through detection, we can find that Ci-tan of Guangdong in modem times once existed at least six Ci-agencies, suah as Yue-tai, Huatian, Helin, Santang, Fengyu, etc. Their emergence was relying on inside development regulation of Ci-xue in Guangdong, influence of tradition of forming agencies in the literary circles of Guangdong, violent of situation change, community realize to build up and the exist of a huge Ci-xue networks that was coagulate with blood relationship, the native place relationship and teachers and friends relation. Ci-agency of Guangdong in modem times were an important token of the prosperous creations of Guangdong in modem times. Investigating and discussing Ci-agency of Guangdong in modem times can provide a beneficial observation angle for completely delineating and thoroughly understanding Ci-history of Guangdong in modem times.

APA, Harvard, Vancouver, ISO, and other styles

Journal articles on the topic 'Yue du jiao xue'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles